Today: 10 June 2026
CBA share price: Australia Day closure tees up CPI and February earnings test for Commonwealth Bank stock
26 January 2026
2 mins read

CBA share price: Australia Day closure tees up CPI and February earnings test for Commonwealth Bank stock

Sydney, January 26, 2026, 16:49 AEDT — Trading has wrapped up for the day.

Commonwealth Bank of Australia shares will not trade on Monday, with the ASX cash market shut for the Australia Day holiday. Investors won’t get a fresh look at the stock until trading resumes Tuesday. The week ahead is short, but inflation and interest rate forecasts remain front and center.

This is significant because CBA is Australia’s biggest listed lender and a major market force, so even small policy shifts can move large amounts of capital. Banks also factor in expectations for net interest margin — the gap between income from loans and expenses on deposits.

CBA closed Friday at A$149.48, down 0.75%. The stock has fallen in four of the past five sessions and is off about 6.9% since its Dec. 29 close. On that day, ANZ Group slipped 0.5%, and National Australia Bank dipped 0.2%.

Westpac chief economist Luci Ellis highlighted the “trimmed mean” inflation figure—a core gauge that filters out the most volatile price swings—as a likely factor in the Reserve Bank’s decision in early February. Westpac’s nowcast puts trimmed mean inflation at 0.7% for the quarter. Westpaciq

ANZ economists Adam Boyton and Aaron Luk pointed out that the surprise fall in unemployment makes a February rate hike “more likely at the margin,” even though they still view inflation as the main driver. NAB senior economist Taylor Nugent expects trimmed mean inflation to hit about 0.9%, with travel and new-car prices leading the upward push. SmartCompany

Last week, Commonwealth Bank economist Harry Ottley pointed to strong jobs data as a clear reason to expect a rate hike in February, with the cash rate forecast rising to 3.85%. He called the upcoming CPI report “the next big test” for the central bank. CommBank

HSBC chief economist Paul Bloxham highlighted a “tangible risk” of an RBA rate hike in February, even though the bank’s primary forecast expects tightening to come later in the year. He added that if the RBA did move that fast, describing it as “finetuning” would be hard to justify. Financial Newswire

The Reserve Bank’s monetary policy board will convene on Feb. 2-3. Traders at the bank are watching that date carefully—it’s the next major policy milestone following the release of inflation data.

CBA is gearing up for its half-year results and interim dividend announcement on Feb. 11. The ex-dividend date is slated for Feb. 18, and the interim dividend payment is expected around March 30.

Morningstar analyst Nathan Zaia called out CBA for trading at “a steep premium” relative to his A$100 fair value estimate. He cautioned that this gap could exaggerate market reactions to surprises in margins, costs, or credit quality. On Jan. 23, Morningstar put the stock’s premium at 49% above that target. Morningstar

The real risk is a hotter inflation figure that ramps up rate-hike expectations, which could hit a market already factoring in steady conditions. A softer reading might calm policy worries but could spark new concerns about loan growth and household stress early in the year.

The consumer price index for the December quarter is set for release on Wednesday, Jan. 28, at 11:30 a.m. AEDT.

Stock Market Today

  • MindWalk Launches ReefIQ for Enhanced AI-Driven Drug Discovery
    June 10, 2026, 9:49 AM EDT. MindWalk Holdings Corp. (NASDAQ: HYFT) introduced ReefIQ™, a biological context layer designed to unify fragmented drug discovery data for AI analysis. The technology integrates diverse biological information such as sequences, structures, and assay results into a governed, queryable network. This enables MindWalk's LensAI tool and client-selected models to perform more accurate hypothesis generation and target discovery. By preserving data provenance and program history, ReefIQ aims to enhance trust and efficiency in regulated drug development environments. CEO Dr. Jennifer Bath emphasized that ReefIQ closes the data gaps in biological context, crucial for reliable AI-driven insights in life sciences.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
ON Semiconductor stock price slips into the weekend — what to watch before Monday’s trade
Previous Story

ON Semiconductor stock price slips into the weekend — what to watch before Monday’s trade

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks
Next Story

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks

Go toTop